AFT signs North American licensing deal for Pascomer topical treatment

AFT signs North American licensing deal for Pascomer topical treatment
Paul McBeth
By Paul McBeth July 5 (BusinessDesk) - AFT Pharmaceuticals is eyeing a US$10 million payment from a North America licensing deal but is keeping its earnings guidance unchanged for now.  The maker of Maxigesic painkillers reached the licensing and development agreement with US-based Timber Pharmaceuticals for its Pascomer drug, which treats skin lesions known as facial angiofibromas associated with the genetic disorder, tuberous sclerosis.  Timber will cover the cost of two clinical trials involving 120 patients, with the results due ne...

More Services

Aussie fund manager Shaws buys Devon Funds
Finance

Aussie fund manager Shaws buys Devon Funds

The deal is the latest tie-up between Australian and NZ funds managers.

Staff reporters 24 Jun 2025
Buy NZ Made's new service trademark sets high bar
Services

Buy NZ Made's new service trademark sets high bar

One certified business says it sets it apart from multinational competitors.

John Anthony 23 Jun 2025
Reel pain: Strikes hit NZ cinemas, profits dive
Services

Reel pain: Strikes hit NZ cinemas, profits dive

Cinema chains in NZ face box office suspense.

Victoria Young 28 May 2025
PEP seeking payday from UP Education
Finance

PEP seeking payday from UP Education

UP Education is a NZ success story in Australia.

Pattrick Smellie 23 Apr 2025